What is claimed is:

1. A method for treating cholinergically induced smooth muscle hyperactivity disorders, comprising the administration to a mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of R,S-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, R(+)-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropyl amine, RS-*N*-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or R(+)-*N*-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein said compound is R,S-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

3. The method of claim 1, wherein said compound is R(+)-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropyl amine, or a pharmaceutically acceptable salt thereof.

4. The method of claim 1, wherein said compound is RS-*N*-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

5. The method of claim 1, wherein said compound is R(+)-*N*-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

6. A method for treating cholinergically induced smooth muscle hyperactivity disorders, comprising the administration to a mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of R,S-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, R(+)-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, RS-*N*-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine, R(+)-*N*-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl) phenyl)-3-phenylpropylamine, RS-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or R(+)-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl) phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof, while reducing or eliminating concomitant liability of adverse side effects associated with the corresponding parent compounds, those parent compounds being RS-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine and R(+)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine.

7. The method of claim 6, wherein said compound is R,S-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

8. The method of claim 6, wherein said compound is R(+)-*N*-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

9. The method of claim 6, wherein said compound RS-*N*-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

10 The method of claim 6, wherein said compound is R(+)-*N*-Isopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

11. The method of claim 6, wherein said compound is RS-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

12. The method of claim 6, wherein said compound is R(+)-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine or a pharmaceutically acceptable salt thereof.

13. The method of claim 6, wherein said disorders are selected from the group consisting of urinary incontinence and pollakiuria.

14. The method of claim 6, wherein said compound or a pharmaceutically acceptable salt thereof is administered in a dose from about 0.5 mg to about 100 mg per day.

15. The method of claim 6, wherein said compound or a pharmaceutically acceptable salt thereof is administered by inhalation or by parenteral, transdermal, rectal, sublingual or oral administration.

16. The method of claim 6, wherein said compound or a pharmaceutically acceptable salt thereof is administered orally in the pharmaceutical unit dosage form of a tablet or capsule.

17. The pharmaceutical unit dosage form of claim 16. wherein said tablet or capsule is formulated for controlled release upon administration.